William Cobb
Endocrinology, Diabetes & Metabolism · Milton, MANPI 1619927670
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 392 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,133 and has fallen 99.3% since, to $21 in 2025.
Across 392 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$804
- Amgen$660
- Lilly USA, LLC$458
- Boehringer Ingelheim$447
- AbbVie$421
- plus $3K from 27 others
What the payments were for
- Food & beverage$6,763100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 123 | $1,259 |
| AstraZeneca | 36 | $804 |
| Amgen | 27 | $660 |
| Lilly USA, LLC | 27 | $458 |
| Boehringer Ingelheim | 22 | $447 |
| AbbVie | 20 | $421 |
| Merck | 20 | $343 |
| Sanofi-aventis U.S. LLC | 17 | $337 |
| Amarin Pharma, Inc. | 7 | $256 |
| Vifor Pharma, Inc. | 14 | $240 |
| Valeritas, Inc. | 5 | $198 |
| Lifescan, Inc. | 10 | $178 |
| Johnson & Johnson | 12 | $175 |
| Corcept Therapeutics | 8 | $161 |
| Esperion Therapeutics, Inc. | 7 | $119 |
| Insulet Corporation | 4 | $103 |
| Regeneron Healthcare Solutions, Inc. | 4 | $100 |
| Medtronic(2 entities) | 4 | $84 |
| Pfizer | 4 | $66 |
| Bayer | 2 | $49 |
| Xeris Pharmaceuticals, Inc. | 3 | $47 |
| Radius Health, Inc. | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| OPKO Pharmaceuticals, LLC | 1 | $23 |
| IBSA Pharma Inc. | 1 | $21 |
| Amryt Pharma Holdings Ltd | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Akebia Therapeutics Inc | 2 | $18 |
| Alfasigma USA, Inc. | 1 | $18 |
| Tandem Diabetes Care, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,786 in reported general payments places this provider in the 75th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Other endocrinology, diabetes & metabolism in Milton
- Jason GagliaBoston$2.4M
- Tamer YacoubFall River$775K
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Nitin TrivediWorcester$403K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Peter ButlerFlorence$216K
- Augusto Caballero-RoblesBoston$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.